Community Research and Development Information Service - CORDIS

FP6

HIV VIROSOMES — Result In Brief

Project ID: 12183
Funded under: FP6-LIFESCIHEALTH
Country: Austria

Liposomal technology to help develop HIV vaccine

Scientists are hard-pressed to develop a safe and effective vaccine to halt the spread of HIV, especially in developing countries.
Liposomal technology to help develop HIV vaccine
The 'Development of a new vaccine against HIV: virosomes incorporating HIV proteins' (HIV virosomes) project had as its objective the development of a preventive HIV vaccine based on a direct approach from laboratory to proof-of-concept studies in non-human primates. Researchers proposed testing virus-like particles (VLPs) that would incorporate primary HIV or recombinant proteins with native conformation into liposomes.

The liposomes, with predefined properties, were generated as required using an earlier established, large-scale liposomal technology. The resulting virosomes were used as a prophylactic and therapeutic vaccine against HIV-1 infection.

Project researchers succeeded in stabilising the composition and conformation of native and recombinant HIV envelope proteins in liposomes. On the strength of small animal immunisation studies, HIV virosomes project members were also able to choose candidate vaccines. They successfully established immunogenicity and, eventually, efficacy in their rhesus macaque model, and established a process in line with good manufacturing practices (GMP) for production of clinical material.

The project's results hold potential in its technological advances and approach design. And, importantly, the low production cost of the vaccine, its stable features and possibility for administration in needle-free form make it an ideal approach that could fulfil the needs of developing countries.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top